RESUMEN
AIMS: Neither clinical nor financial comparisons yet exist between self-expanding metallic stents (SEMS) and laser therapy, concentrating on the treatment of obstructive adenocarcinomas of the oesophagogastric junction. The aim of our study was to compare the relative lifetime costs and clinical results of the Nd:YAG laser to those of SEMS as alternative forms of primary palliation of dysphagia for adenocarcinoma near the oesophagogastric junction. METHODS: Fifty-two patients with distal oesophageal or oesophagogastric adenocarcinomas underwent palliative treatment for dysphagia: 32 treated with laser therapy and 20 with SEMS in this retrospective study. The clinical outcome and real cumulative costs as physical units and in financial terms were analysed for these study groups. RESULTS: Although patients palliated with SEMS underwent fewer procedures (1.9+/-1.6 vs 3.4+/-4.0, P=0.0048) and spent less time in endoscopic theatre (38+/-25min vs 118+/-152min, P=0.0048), they spent as many days in hospital (12.9 vs 15.1, P=0.370) and required as high overall costs for therapy (5360 EUR vs 5450 EUR, P=0.679) as those treated with laser therapy. In addition, they had higher morbidity rates (30 vs 6.3%, P=0.043), hospital mortality (20 vs 3.1%, P=0.066), and 30-day mortality (40 vs 3.1%, P=0.0011) than did patients with laser therapy, with no evidence of SEMS being the more effective treatment modality. CONCLUSIONS: In patients with adenocarcinoma at the distal oesophagus or at the oesophagogastric junction, laser therapy palliates dysphagia effectively with lower morbidity and mortality rates and without increased costs or hospital stays than does use of self-expanding metallic stents.
Asunto(s)
Adenocarcinoma/cirugía , Trastornos de Deglución/cirugía , Neoplasias Esofágicas/cirugía , Unión Esofagogástrica , Coagulación con Láser , Cuidados Paliativos , Stents , Adenocarcinoma/complicaciones , Adenocarcinoma/patología , Anciano , Anciano de 80 o más Años , Costos y Análisis de Costo , Trastornos de Deglución/etiología , Neoplasias Esofágicas/complicaciones , Neoplasias Esofágicas/patología , Esofagoscopía/economía , Femenino , Humanos , Coagulación con Láser/economía , Tiempo de Internación , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Cuidados Paliativos/economía , Estudios Retrospectivos , Stents/economía , Resultado del TratamientoRESUMEN
Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the cases detected by screening will be very long and detriments in quality of life could have a major impact on the subjects remaining life-span. A framework within which both HRQL and cost-effectiveness of prostate cancer screening can be assessed is presented. Studies of both are ongoing in the European Randomised Study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. Preliminary information confirms that it is important to study screened subjects and controls, and not to assume that inferences derived from study of prostate cancer outside screening trials can be extrapolated to the trials. However, it will require prolonged study to enable the overall effects on quality of life, and on cost-effectiveness to be determined. Such studies are ongoing for the two trials.
Asunto(s)
Tamizaje Masivo/economía , Neoplasias de la Próstata/diagnóstico , Calidad de Vida , Neoplasias del Colon/diagnóstico , Neoplasias del Colon/economía , Análisis Costo-Beneficio , Femenino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/economía , Masculino , Neoplasias Ováricas/diagnóstico , Neoplasias Ováricas/economía , Neoplasias de la Próstata/economía , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: Screening for familial abdominal aortic aneurysms (AAA) is widely recommended. To analyze cost-effectiveness of screening for familial AAAs incremental cost-effectiveness (C/E) analysis based on an ultrasound screening among relatives and a decision model of screening program was compared to a baseline situation without systematic screening. PATIENTS AND METHODS: 74% (238/322) of first-degree relatives of 150 consecutive AAA patients were screened at HUCH (Helsinki University Central Hospital). Effectiveness and costs of treatment were assessed using the Finnish Hospital Discharge Register and from survival analysis of 1130 AAA patients who underwent elective or emergency surgery in HUCH. To form incremental C/E-ratios the existing clinical practice was compared to a screening program for male siblings. Hypothetical screened and control cohorts of 1000 male relatives were used to create the decision model. Parameters in C/E-analyses were derived from our own data except for growth and rupture rates. A sensitivity analysis was carried out. RESULTS: The incremental effectiveness in life-years gained by the screening of male siblings was 92 years with incremental C/E-ratio of FIM 33,000 ($6200). According to sensitivity analysis the C/E-ratios were robust for all variables tested. CONCLUSIONS: Screening of male siblings of AAA patients produces incremental life-years at low cost thus screening of male siblings is highly recommended.
Asunto(s)
Aneurisma de la Aorta Abdominal/economía , Tamizaje Masivo/economía , Anciano , Aneurisma de la Aorta Abdominal/genética , Aneurisma de la Aorta Abdominal/mortalidad , Análisis Costo-Beneficio , Finlandia , Humanos , Masculino , Persona de Mediana Edad , Análisis de SupervivenciaRESUMEN
OBJECTIVES: This article reports a cost-effectiveness analysis of targeted screening for abdominal aortic aneurysm (AAA). A major emphasis was on the estimation of distributions of costs and effectiveness. METHODS: We performed a Monte Carlo simulation using C programming language in a PC environment. Data on survival and costs, and a majority of screening probabilities, were from our own empirical studies. Natural history data were based on the literature. RESULTS: Each screened male gained 0.07 life-years at an incremental cost of FIM 3,300. The expected values differed from zero very significantly. For females, expected gains were 0.02 life-years at an incremental cost of FIM 1,100, which was not statistically significant. Cost-effectiveness ratios and their 95% confidence intervals were FIM 48,000 (27,000-121,000) and 54,000 (22,000-infinity) for males and females, respectively. Sensitivity analysis revealed that the results for males were stable. Individual variation in life-year gains was high. CONCLUSIONS: Males seemed to benefit from targeted AAA screening, and the results were stable. As far as the cost-effectiveness ratio is considered acceptable, screening for males seemed to be justified. However, our assumptions about growth and rupture behavior of AAAs might be improved with further clinical and epidemiological studies. As a point estimate, females benefited in a similar manner, but the results were not statistically significant. The evidence of this study did not justify screening of females.
Asunto(s)
Aneurisma de la Aorta Abdominal/diagnóstico por imagen , Análisis Costo-Beneficio , Tamizaje Masivo/economía , Anciano , Anciano de 80 o más Años , Aneurisma de la Aorta Abdominal/economía , Humanos , Masculino , Tamizaje Masivo/métodos , Persona de Mediana Edad , Método de Montecarlo , UltrasonografíaRESUMEN
Taurine content of 199 clinical muscle biopsies was determined and correlated to histometric data of 121 cases. Taurine concentration in muscles was markedly dependent on fiber type distribution, taurine being more abundant in the slow, oxidative type 1 fibers than in the type 2 fibers. Taurine concentration rose slightly with age and tended to be higher in denervations, muscular dystrophies and myotonias, but the differences from the control values were non-significant.